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Abstract
Introduction: The prognosis of patients with HIV in Africa has improved with the widespread use of antiretroviral therapy
(ART) but these successes are threatened by low rates of long-term retention in care. There are limited data on predictors of
retention in care, particularly from rural sites.
Methods: Prospective cohort analysis of outcome measures in adults from a rural HIV care programme in Madwaleni,
Eastern Cape, South Africa. The ART programme operates from Madwaleni hospital and seven primary care feeder clinics
with full integration between inpatient and outpatient services. Outreach workers conducted home visits for defaulters.
Results: 1803 adults initiated ART from June 2005 to May 2009. At the end of the study period 82.4% were in active care or
had transferred elsewhere, 11.1% had died and 6.5% were lost to follow-up (LTFU). Independent predictors associated with
an increased risk of LTFU were CD4 nadir .200, initiating ART as an inpatient or while pregnant, and younger age, while
being in care for .6 months before initiating ART was associated with a reduced risk. Independent factors associated with
an increased risk of mortality were baseline CD4 count ,50 and initiating ART as an inpatient, while being in care for .6
months before initiating ART and initiating ART while pregnant were associated with a reduced risk.
Conclusions: Serving a socioeconomically deprived rural population is not a barrier to successful ART delivery. Patients
initiating ART while pregnant and inpatients may require additional counselling and support to reduce LTFU. Providing HIV
care for patients not yet eligible for ART may be protective against being LTFU and dying after ART initiation.
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Introduction
Data from multiple sources show that antiretroviral treatment
(ART) dramatically improves the prognosis of individuals with
HIV infection and universal access to ART is now accepted as an
important part of the integrated response to the epidemic in all
settings [1–7]. It has become increasingly clear that as access to
ART improves the success of services at a population level will
primarily be determined not by issues of drug efficacy but rather
by the effectiveness of drug delivery programmes [8,9].
A major barrier tothe success of ARTprogrammes in Africa may
be low rates of long-term retention in care. A systematic review of
ART programmes in sub-Saharan Africa found that on average
only 64%of patients who initiated ART remain in care after 3 years
[10]. A recent analysis of 44 177 patients attending public sector
ART services in South Africa found that 71% of patients remained
in care after 24 months and 59.6% after 48 months with the
proportion of these being loss to follow-up (LTFU) increasing over
that time [11]. LTFU is the commonest cause of attrition, followed
by death, which is often under-estimated [10].
Despite the increasing allocation of resources to expand access
to ART in sub-Saharan Africa, little is known about how best to
deliver treatment services and in particular how to improve rates
of long-term retention in care. There is a particular lack of
outcome data from ART programmes in low resource rural areas.
The suggestion has also been made that programmes with high
retention rates should serve as models for future improvements
[12].
The aims of our study were to determine the factors predicting
loss to follow-up and mortality in a public-sector HIV and ART
programme in rural South Africa.
Methods
Setting
The Madwaleni HIV wellness and ART programme operates at
Madwaleni Hospital and its 7 primary healthcare feeder clinics. It
is situated in the deeply rural Elliotdale/Xora area of the Mbhashe
sub-district in the Eastern Cape, which is one of the most socio-
economically deprived magisterial districts in South Africa [13].
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speaking with 90% of people living below the poverty line [13].
Catchment population is estimated to be 80 000–100 000 of
whom 60% are adult [14]. HIV prevalence in the Eastern Cape
was estimated in 2005 to be 15.2% in 15–49 years olds [15]. The
programme is predominantly funded by the South African
government with donor support from Aurum Institute for Health
Research and Donald Woods’ Foundation. Stipends were paid to
peer educators and no co-payment was required from patients for
any component of care.
Programme enrolment
Patients testing positive for HIV at one of the healthcare
facilities or at the hospital’s HIV counselling and testing
community based outreach programme were counselled to join
the weekly HIV support groups led by peer educators at one of the
7 feeder clinics. Outpatients were enrolled at their third visit and
pregnant women at their first visit. There was an integrated
inpatient service conducted at the bed-side and inpatients were
enrolled after their second weekly counselling session. Inpatients
not commencing ART while in hospital were referred to the
outpatient programme upon discharge.
Pre-ART care
Patients who were not eligible for ART were encouraged to
attend support groups at feeder clinics 2 weekly for the first 6
months and monthly thereafter. At each visit they received
symptom screening by trained lay counsellors for tuberculosis and
sexually transmitted infections and were referred to a nurse if
symptomatic. Prophylactic co-trimoxazole was prescribed if
patients had a CD4 count ,500 cells/ml or a WHO stage 2, 3
or 4 illness. Women were offered cervical cancer screening.
Isoniazid preventive treatment was introduced in December 2008
for patients without symptoms of active tuberculosis (tuberculin
skin tests were not performed). All patients received multivitamins
and nutritional supplements were provided if their body mass
index was ,18.5 kg/m
2. CD4 count was measured 6 monthly
until patients were eligible for ART.
ART initiation
Eligibility criteria for public sector patients in South Africa were
the same as the 2003 WHO guidelines for resource limited settings
(CD4 lymphocyte count ,200 cells/ml or WHO stage 4 disease)
[16,17]. Eligible patients were enrolled in an ART preparation
programme. Pill counts of co-trimoxazole and/or multivitamins
were done at weekly intervals to assess treatment readiness,
inpatients self administered prescribed medication for this
purpose. Patients who were ineligible for ART underwent this
process as part of pre-ART care. Individual ART adherence
counselling by trained peer educators was done after 3 accurate
pill counts for outpatients or 2 accurate pill counts for inpatients
but accelerated at the discretion of the doctor in clinically unstable
patients. Treatment supporters were sought for patients who were
unable to accurately complete pill counts. Outpatients received a
preparatory home visit and disclosure to household members was
strongly encouraged. All patients who were eligible for ART but
had not initiated therapy were discussed at a weekly team meeting
and followed-up by peer educators by phone call or home visit.
Once prepared, all patients were scheduled to start ART within
7 days and at no point was there a waiting list to begin treatment.
On the day of ART initiation all patients were clinically evaluated
by a doctor who made the final decision to prescribe ART. A
second session of individual ART adherence was conducted by a
pharmacy assistant. ART initiation was temporarily deferred when
patient understanding was inadequate in which case adherence
counselling was repeated and extra social support added whenever
possible. ART was also deferred in order to investigate or treat
opportunistic infections as outlined in national treatment guide-
lines. Inpatient ART was self administered except in those whose
clinical condition precluded adequate counselling (accelerated
inpatient group). The latter group of inpatients were prepared for
self administered ART before hospital discharge.
Follow-up
All patients were followed up 2 weeks after ART initiation to
monitor tolerability and adherence and were then referred back to
the HIV clinic at the feeder clinics for monthly visits for the first
year on ART. After one year adherent patients with an
undetectable viral load were given an option of 3 monthly visits.
All patients who were more than 7 days late for collecting a
prescription were contacted telephonically (seldom available),
otherwise visited at home by an outreach worker.
Task shifting and decentralisation
With increasing patient load exceeding the expansion in clinical
staff the programme focused on extensive task shifting. As a result,
while patients initiating ART early in the programme saw a doctor
at each follow-up visit for the first year, those initiating ART in
later years received much of their follow-up clinical care from
nurses. All patients had access to doctor level care either by
referral from clinic nurses or by self-referral to the hospital
outpatients department.
The programme model sought to decentralise care to the
primary healthcare clinics as much as possible. As a result patients
received every aspect of their care at their closest clinic with the
exception of the day of ART initiation and the 2 week follow-up
visit which took place at the hospital.
Laboratory testing
Baseline blood tests when joining the programme were HIV ELISA,
CD4 count, full blood count, syphilis serology and alanine
aminotransferase (ALT). These were repeated at ART initiation
(except HIV ELISA) if not taken within the preceding 3 months. Viral
load was measured at ART initiation until May 2009 when it was
removedfrom thenational programme.ALT was monitored after 2, 4,
8 & 12 weeks for patients initiating nevirapine. CD4 count, viral load
and full blood count were taken every 24 weeks after ART initiation.
Regimens
First-line ART comprised stavudine (D4T), lamivudine (3TC)
plus a non-nucleoside reverse transcriptase inhibitor (efavirenz or
nevirapine). The dose of D4T was 30 mg for those ,60 kg and
40 mg for those .60 kg until January 2007 when all patients
received D4T 30 mg regardless of weight. The second-line
regimen for those failing the first-line treatment comprised
lopinavir/ritonavir, zidovudine and didanosine. Decisions to
change treatment following step up adherence counselling were
made by a doctor. Co-trimoxazole prophylaxis was stopped when
the CD4 count was .350 cells/ml. The programme experienced
no interruptions in drug supply during the study period.
Ethics
Ethical approval for this study was obtained from the University
of Cape Town Research Ethics Committee. The need for
informed consent from patients was waived as the study
represented enhanced surveillance of data collected as part of
routine patient care.
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Patient enrolment began in January 2005 and the first patients
started ART in June 2005. We included all patients who initiated ART
before the end of May 2009; the end of the study period was 31 August
2009 to allow for at least 3 months of follow-up data on ART. All data
were prospectively entered into a locally developed electronic database
which used Microsoft Access as the frontend and Microsoft Sequel
Server 2005 Express as the backend (Microsoft Corporation, Virginia,
USA). Paper records containing the data along with supplementary
clinical information were kept separately. For the analysis, data storage,
basic calculations and data extraction was handled in Microsoft Sequel
Server 2008. Outcomes analysis was performed in Stata 11.
Frequency distribution and median with interquartile range
(IQR) were used to describe the variables because the distribution
of the continuous variables was found to be non-normal. The
month in which patients started ART was set as month zero. One
day of follow-up was added to patients who did not attend follow-
up after ART initiation for survival analyses.
Multiple Cox proportional hazard regression analysis, adjusted
for competing risks, was used to identify variables associated with a
likelihoodof being LTFU or dying. LTFU was defined as no patient
contact for more than 6 months before the end of study period.
Virological suppression was defined as ,400 copies/ml. Patients
transferring to other centres or LTFU were censored at the date of
their last contact. Variable estimates and their significance at the
95% level were assessed with robust standard errors.
Results
Between January 2005 and May 2009, 3411 adults (.19 years)
were enrolled into the programme. Ninety seven of the 1900
initiating ART by the end of the study period were ART
experienced before enrolling into the programme and were
excluded from further analyses. Baseline characteristics and status
at the end of the study period of the 1803 ART naı ¨ve adults are
summarised in table 1. Median follow-up time on ART was 13.3
months (IQR 5.4 to 25.0) and median time from registration to
starting ARTwas 2 months(IQR 1.0to 4.5). Endof studyoutcomes
forthecombined groupwere71.5%current,11.1%deceased,6.5%
LTFU and 10.9% transferred. For women initiating ART when
pregnant outcomes were 74.5%, 1.1%, 13.6% and 10.9%
respectively. For those initiating ART as inpatients 44.5%,
32.4%, 9.7% and 13.4% respectively, for those taking TB treatment
when initiating ART 61.4%, 16.3%, 6.9% and 10.8% respectively,
for those receiving pre-ART care for .6 months 85.6%, 4.4%,
3.7% and 6.3% respectively and for the 68 patients in the
accelerated inpatient group 28%, 52%, 11% and 11% respectively.
Two hundred and seventy patients who initiated ART had at
least 6 months of pre-ART care; their median CD4 count was 304
(IQR 252 to 386) at enrolment and 192 (IQR 156 to 237) at ART
initiation. The non-nucleoside reverse transcriptase inhibitor used
in first line regimens was efavirenz in 85% and nevirapine in 15%.
Thirteen patients switched to second line ART after a median of
16.8 months (IQR 15.6 to 24.1) on first line therapy. Kaplan-
Meier estimates of LTFU, mortality and retention in care for all
patients are shown in figure 1. After 48 months Kaplan-Meier
estimated LTFU was 11.4%, mortality 16.5%, and loss to care
26.1%. There was a relatively constant attrition rate from LTFU
over the first 36 months whereas mortality was greater in the first
year than subsequent years.
CD4 count and viral suppression rates at 6 monthly intervals
are shown in figure 2. CD4 counts were more likely to be missing
Table 1. Baseline and end of study characteristics of all patients, and specific patient groups.
All
Pregnant when
initiating ART
Inpatient when
initiating ART
Taking TB treatment
when initiating ART .6 months pre-ART care
Number (%) 1803 184 (10.2) 247 (13.7) 583 (32.3) 270 (15.0)
Age (years) baseline
Median 31.9 27.1 32.8 32.3 31.0
IQR (26.8–39.1) (23.4–31.5) (28.2–39.6) (27.7–39.7) (26.3–39.0)
Unknown 179 4 45 73 31
Sex (%)
Female 68.3 100.0 61.3 60.1 81.1
Unknown 9070 0
CD4 count (cells/ml) baseline
Median 123 191 50 76 192
IQR (55–184) (122–248) (21–116) (35–150) (156–237)
Unknown 106 18 42 38 9
Viral load (log10) baseline
Median 4.8 4.3 5.3 5.1 4.5
IQR (4.3–5.4) (3.5–4.7) (4.7–5.8) (4.5–5.6 (3.9–5.0)
unknown 436 52 107 39 56
Status at end of study (%)
Current 71.5 74.5 44.5 61.4 85.6
Deceased 11.1 1.1 32.4 16.3 4.4
LTFU 6.5 13.6 9.7 6.9 3.7
Transferred 10.9 10.9 13.4 10.8 6.3
doi:10.1371/journal.pone.0019201.t001
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specimens to the laboratory (CD4 counts need to be processed
more rapidly than viral loads after venepuncture). Cox propor-
tional hazard ratios for death and LTFU according to baseline
parameters are shown in tables 2 and 3 respectively. Risk of dying
was independently associated with lower CD4 counts and starting
ART as an inpatient. Being pregnant when starting ART and
receiving .6 months pre-ART care were associated with
decreased risk of dying. Risk of becoming lost to follow-up was
independently associated with higher CD4 count, younger age,
starting ART as an inpatient and starting ART while pregnant.
Receiving .6 months pre-ART care was associated with a
decreased risk of becoming lost to follow-up. There was a time
dependent association between risk of death and being an
inpatient when starting ART, with increased mortality in the first
month (data not shown). We therefore conducted a sub-analysis
excluding deaths in the first month. The association between death
and starting ART as an inpatient was weakened but remained
significant (adjusted hazard ratio 2.15, 95% confidence interval
1.28 to 3.62).
Discussion
Our study shows that serving a highly socio-economically
deprived rural population is not a barrier to successful ART
delivery. Estimated four year loss to follow-up rates reported from
Figure 2. Median CD4 cell count (bars indicate interquartile range) and proportion with HIV viral load suppressed (bar indicates
lower 95% confidence interval) at 6 monthly intervals.
doi:10.1371/journal.pone.0019201.g002
Figure 1. Kaplan-Meier estimates of LTFU, mortality and loss to care by months of treatment with ART for 1803 ART naive adults.
doi:10.1371/journal.pone.0019201.g001
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[10,11]. To our knowledge the estimated loss to follow-up rate of
11.4% at four years is lower than any reported from a resource
limited setting. A major strength of our programme is that it fully
integrates care for inpatients, pregnant women, and patients not
yet eligible for ART. Despite higher overall mortality, particularly
in the first month, we show that patients can be successfully started
on ART while in hospital, but rates of LTFU are higher. Women
initiating ART while pregnant have a significant survival
advantage although they are at greater risk of becoming LTFU.
Importantly, patients with .6 months pre-ART care have both
decreased mortality and LTFU after starting ART.
The low rate of LTFU in the Madwaleni programme may be
explained by the inclusion of many factors known to reduce
LTFU. Proven effective strategies include improved patient
preparation [18], use of treatment supporters [19], reduced
patient costs [20], improved databases [21] and community
support [22]. Our model includes at least 3 individual counselling
sessions before starting ART with ongoing group education at
support groups. Almost all patients had treatments supporters,
decentralisation of services to peripheral clinics reduced patient
costs, and an electronic database allowed prompt identification of
treatment defaulters who were actively followed-up by phone and
home visit.
The formation of active support groups within the community
was likely an important factor in the overall success of the model.
Importantly, support groups included patients not yet eligible for
ART allowing group numbers to increase more quickly and
possibly reduce HIV related stigma in the community. The
community network of HIV positive people was then able to
identify at risk patients and inform staff members of problems.
Our estimated 4 year mortality was higher than in other South
African ART programmes [11]. A likely explanation for the higher
mortality in our cohort is the inclusion of 247 inpatients starting
ART who accounted for approximately 40% of all deaths. Patients
who require hospitalisation typically have advanced disease and
Table 3. Cox proportional hazard ratio of risk of loss to follow-up.
Variables Hazard Ratio (95% confidence intervals) p-value
Baseline CD4 count (cells/ml) 0–49
50–199
$200
1.00 (0.61 to 1.64)
Referent
1.74 (1.09 to 2.78)
0.991
NA
0.019
Sex Male
Female
Referent
1.42 (0.90 to 2.23)
NA
0.134
Age (years) ,25
25–50
.50
1.87 (1.15 to 3.05)
Referent
1.2 (0.70 to 2.06)
0.012
NA
0.51
Starting ART as an inpatient Yes
No
1.89 (1.06 to 3.38)
Referent
0.032
NA
Starting ART on tuberculosis treatment Yes
No
1.03 (0.63 to 1.68)
Referent
0.904
NA
Starting ART in pregnancy Yes
No
3.20 (1.86 to 5.51)
Referent
,0.001
NA
Pre-ART care .6 months Yes
No
0.49 (0.24 to 1.00)
Referent
0.05
NA
doi:10.1371/journal.pone.0019201.t003
Table 2. Cox proportional hazard ratio of risk of dying.
Variables Hazard Ratio (95% confidence intervals) p-value
Baseline CD4 count (cells/ml) 0–49
50–199
$200
1.76 (1.23 to 2.52)
Referent
1.17 (0.73 to 1.86)
0.002
NA
0.515
Sex Male
Female
Referent
1.20 (0.87 to 1.66)
NA
0.279
Age (years) ,25
25–50
.50
0.69 (0.39 to 1.24)
Referent
1.33 (0.92 to 1.93)
0.214
NA
0.132
Starting ART as an inpatient Yes
No
2.91 (1.90 to 4.47)
Referent
,0.001
NA
Starting ART on tuberculosis treatment Yes
No
1.15 (0.77 to 1.72)
Referent
0.494
NA
Starting ART in pregnancy Yes
No
0.18 (0.04 to 0.74)
Referent
,0.001
NA
Pre-ART care .6 months Yes
No
0.50 (0.26 to 0.96)
Referent
0.037
NA
doi:10.1371/journal.pone.0019201.t002
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therefore be excluded from mortality estimates. Another possibility
is that the community network allowed better ascertainment of
death than in other programmes where many patients who are
listed as LTFU may have died.
A number of factors could account for the higher rate of LTFU
in inpatients and pregnant women in our cohort. Firstly,
accelerated ART initiation reduces both the time patients have
to prepare for treatment and the number of counselling and
support group sessions they can attend. Secondly, patients who test
for HIV because of illness, as occurred in most of our inpatients
starting ART, or those attending for non-HIV related reasons such
as pregnancy are more likely to be non-adherent than those testing
because of possible exposure to HIV [23]. Thirdly, depression,
which is known to impair adherence to ART [24], is more
common in patients with symptomatic than asymptomatic HIV
[25]. The prevalence of depression is very high during pregnancy
and in the postnatal period in sub-Saharan Africa, particularly in
women who know they are HIV-infected [26–28]. Women may
have less reason to attend a health facility post delivery and need
extra time at home to care for the newborn while the inpatients
may have been drawn from a wider geographical area due to the
severity of their illness and have had further to travel for care after
discharge. The increased rate of LTFU in patients with CD4 nadir
.200 we observed in our cohort was also reported from another
South African ART programme [29]. Under South African
guidelines pertaining at the time of our study patients with CD4
.200 were eligible for ART only if they had a WHO stage 4
illness. Therefore, patients in our cohort with CD4 nadir .200
were symptomatic and their higher rate of LTFU might be due the
same explanations proposed above for patients starting ART as
inpatients.
Although some data are conflicting [30] most studies of women
starting ART when pregnant have found an increase in LTFU
[31,32]. The same studies mostly failed to show a difference in
overall survival [30,32] although a small survival advantage was
found in a single study [31]. Our data suggest that being pregnant
when initiating ART is associated with increased LTFU and
decreased mortality. One explanation for the lower mortality we
observed in women starting ART when pregnant is that CD4
counts are transiently lowered in pregnancy due to haemodilution
[33]. Therefore controlling for CD4 counts at ART initiation in
our Cox proportional hazards model of survival confers a survival
benefit to pregnant women.
Our finding that patients with .6 months pre-ART care had
decreased mortality and LTFU after starting ART suggests that
providing comprehensive follow-up care for patients not yet
eligible for ART will improve outcomes. Many African ART
programmes focus most or all of their time on patients who need
ART. Data from the private sector in South Africa showed that
patients with .6 months CD4 monitoring prior to ART initiation
incurred lower direct costs and had decreased mortality [34,35].
A limitation of our study, common to all observational studies, is
that despite adjustment for potential confounders the possibility of
residual confounding exists. The definition we used of LTFU was
the same as that used in comparable studies [11,36]. However, this
definition takes no account of unstructured treatment interruptions
before the last 6 months of the study period. Civil identification
numbers were not widely available and therefore cross referencing
with the national death registry was not possible. Ascertainment of
death when not observed in our hospital was often based on
information from the community. However, we believe this
information was fairly complete as it was based on information
obtained from home visits by outreach workers. Our model used
additional donor funding which may limit the ability to generalize
our findings to other settings. However, the programme is
primarily state funded to ensure sustainability and while donor
funding was important in establishing the model it was only
accepted for costs that could feasibly be replaced by state funding
in future.
More data are required to better understand the reasons for
higher rates of LTFU in patients starting ART during pregnancy
or as inpatients, in order to develop strategies to reduce LTFU.
Our data suggest that pre-ART care improves outcomes but
further analysis of both the costs and benefits of providing
comprehensive HIV care services is required.
In summary, the success of ART delivery in Africa is threatened
by low rates of retention in care and particularly by high rates of
LTFU. Our study shows that low rates of LTFU are achievable,
even in remote rural areas, by focusing on activities proven to
decrease loss to follow-up, by building a strong community support
network, and by introducing active pre-ART care. ART
programmes in Africa may be able to improve rates of retention
in care by adapting this programme model to their own settings.
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